临床进展恒瑞医药公告简讯
恒瑞瑞布帕肽T2DM III期达到主要终点，HbA1c最高降2.67%
恒瑞公告HRS9531-302 III期顶线结果：瑞布帕肽2mg和4mg组在36周的HbA1c较基线分别下降2.37%和2.67%，均优于匹配安慰剂；公司计划在中国提交2型糖尿病新药上市申请。
原文标题：Latest News 2026-07-20 HbA1c Reduction of Up to 2.67%: Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial in China of GLP-1/GIP Dual Receptor Agonist Ribupatide Injection in Treatment-Naïve T2DM Patients